Testing a combination treatment for advanced colorectal cancer affecting the liver

Plain-English translation of NCT06563986 on ClinicalTrials.gov ↗ · Source last updated August 2024 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether trifluridine/tipiracil (FTD-TPI), combined with bevacizumab (an antibody that blocks blood vessel growth) and a special radiation treatment using holmium-166 microspheres, can help people with advanced colorectal cancer that has spread to the liver. The cancer in these patients has stopped responding to previous chemotherapy treatments. Researchers believe this medication combination may work better when paired with the radiation treatment than either approach alone.

Many people with advanced colorectal cancer that spreads to the liver eventually stop responding to standard chemotherapy. This trial exists to see whether adding a targeted radiation treatment to the medication can improve how well the treatment works and help patients live longer.

Do you qualify?

You likely qualify if…

you have been diagnosed with colorectal cancer that has spread to the liver and cannot be surgically removed
your cancer has grown or you could not tolerate previous treatments that included three specific types of chemotherapy
you are at least 18 years old and in good enough health to receive anti-cancer antibody treatment
your liver tumors take up between 10% and 50% of your total liver volume
you have adequate blood cell counts and kidney and liver function as measured by blood tests

You likely don't qualify if…

you have significant cancer spread outside the liver, such as many lung nodules or cancer in the abdominal lining
you could be treated instead with surgery or other local cancer-removal techniques
you have serious heart or blood vessel disease, uncontrolled high blood pressure, or a history of severe bleeding
you have received chemotherapy in the past 4 weeks or previous radiation treatment to the liver
you are pregnant, breastfeeding, or weigh more than 330 pounds

What participation looks like

Over the course of the study, you will receive the medication combination through infusions and pills given in 4-week cycles. You will also undergo a specialized radiation procedure where tiny radioactive beads are delivered directly to the liver tumors. Throughout your participation, you will have regular blood tests and imaging scans to monitor how well the treatment is working and to check for any side effects. The study will track your health and cancer response over time.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(1 site)

Netherlands

UMC Utrecht, Utrecht